OptimizeRx Enters New Credit Agreement, Terminates Old One and Reports First-Quarter Results
OptimizeRx Corp executed a new credit agreement, terminated its prior credit agreement and recorded a new direct financial obligation. The moves alter the company's borrowing arrangements while first-quarter financial results now sit on record with the SEC.
insidermonkey.comOptimizeRx Corp (OPRX) entered a material definitive credit agreement, terminated a prior material definitive credit agreement and created a direct financial obligation, according to an 8-K filed with the SEC on May 12, 2026.
The filing discloses actions under Items 1.01, 1.02, 2.03 and 2.02. Item 1.01 covers entry into the new credit agreement. Item 1.02 covers termination of the previous credit agreement. Item 2.03 covers creation of the direct financial obligation. Item 2.02 covers results of operations and financial condition for the quarter ended March 31, 2026.
Item 9.01 includes exhibits and financial statements.
The new credit agreement replaces the terminated agreement and establishes fresh borrowing terms for the company. The prior agreement no longer governs OptimizeRx's debt arrangements. The filing does not disclose the exact dollar size of the new facility or the terminated facility. The change took effect on or before the May 12, 2026 filing date.
Operationally the company now operates under the covenants, interest rates and maturity terms of the new agreement instead of the prior one. The creation of the direct financial obligation requires OptimizeRx to meet repayment and reporting obligations spelled out in the new contract.
The results of operations disclosure places the company's first-quarter revenue, expenses and net income on the public record, allowing investors and counterparties to evaluate performance under the updated capital structure.
Downstream the new agreement triggers any required notices to prior lenders, potential collateral releases and compliance with updated financial covenants. The company must observe contractual milestones such as quarterly reporting deadlines and interest-payment dates under the new facility.
Future material amendments or further terminations would require additional 8-K filings. The first-quarter results now become the baseline for measuring performance against the new credit terms in subsequent periodic reports.
This filing constitutes the latest update to OptimizeRx's capital structure. The company last reported material debt-related events in prior 8-K filings that disclosed earlier credit facilities and amendments. Standard SEC rules require Exhibit 10.1 for the new agreement and Exhibit 99.1 or similar for the financial results press release, both included under Item 9.01.
Primary sources: SEC Form 8-K filed May 12, 2026 · OptimizeRx Corp EDGAR archive.
Coverage spread
Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.
No mainstream coverage of this story has surfaced yet.
Transparency Panel
Related Stories
ibtimes.comSEC Chair Paul Atkins Says Congress Will Pass Crypto Legislation
SEC Chair Paul Atkins stated he is confident Congress will pass crypto market structure legislation. He added that President Trump will sign the bill into law.
asiaone.comIran Says Strait of Hormuz Management Belongs to Iran and Oman
Iran's Foreign Ministry spokesperson stated that control of the Strait of Hormuz must be decided solely by Iran and Oman. The spokesperson also said no agreement has been reached with the United States and that current focus remains on ending the war.
cnbc.comFed Official Highlights Regulatory Barriers to AI Productivity Gains
A Federal Reserve official stated that productivity growth remains key to economic expansion and that regulatory hurdles are the main obstacle to sustained gains from artificial intelligence.